AR091185A1 - Derivados de 1,2,4-triazol - Google Patents
Derivados de 1,2,4-triazolInfo
- Publication number
- AR091185A1 AR091185A1 ARP130101863A AR091185A1 AR 091185 A1 AR091185 A1 AR 091185A1 AR P130101863 A ARP130101863 A AR P130101863A AR 091185 A1 AR091185 A1 AR 091185A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- heterocycloalkyl
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos inhiben la PDE10A y pueden utilizarse como medicamentos. Reivindicación 1: Un compuesto de la fórmula (1) ó (2) en las que: B es alquileno C₁₋₄, alquenileno C₂₋₄, alquinileno C₂₋₄, cicloalquilo C₃₋₅; R¹ y R² se eligen con independencia entre hidrógeno, alquilo C₁₋₇ opcionalmente sustituido por cicloalquilo C₃₋₅; hidroxialquilo C₁₋₇, alcoxialquilo C₁₋₇, haloalquilo C₁₋₇, cicloalquilo C₃₋₅, R¹ y R² junto con el átomo de nitrógeno, al que están unidos, forman un azaespirocicloalquilo, un anillo bicíclico o un heterocicloalquilo que pueden estar sustituidos de 1 a 3 veces por sustituyentes elegidos con independencia entre el grupo formado por halógeno, alquilo C₁₋₇, alcoxialquilo C₁₋₇; hidroxi-alquilo C₁₋₇, alcoxi C₁₋₇, haloalquilo C₁₋₇, hidroxilo, -NR⁹R¹⁰ y oxo; R³ se elige entre hidrógeno, cicloalquilo C₃₋₅, alcoxialquilo C₁₋₇, haloalquilo C₁₋₇, heterocicloalquilo, -(CH₂)₀,₁,₂-arilo opcionalmente sustituido por alcoxi C₁₋₇ y alquilo C₁₋₇ opcionalmente sustituido por cicloalquilo C₃₋₅; R⁴ se elige entre heteroarilo opcionalmente sustituido de 1 a 3 veces por sustituyentes elegidos entre halógeno, alquilo C₁₋₇, hidroxialquilo C₁₋₇, haloalcoxi C₁₋₇, halo-alquilo C₁₋₇, cicloalquilo C₃₋₅, ciano, amino, nitro, -O-R⁶-C(O)-R⁷, -SO₂R⁸, alcoxi C₁₋₂ opcionalmente sustituido por alcoxi C₁₋₂, heterocicloalquilo; R⁶ y R⁸ se eligen entre alquilo C₁₋₇; R⁷ se elige entre heterocicloalquilo; R⁹ y R¹⁰ se eligen con independencia entre hidrógeno, alquilo C₁₋₇, -C(O)-O-alquilo C₁₋₇.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12169954 | 2012-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091185A1 true AR091185A1 (es) | 2015-01-14 |
Family
ID=48534382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101863 AR091185A1 (es) | 2012-05-30 | 2013-05-29 | Derivados de 1,2,4-triazol |
Country Status (21)
Country | Link |
---|---|
US (1) | US9394311B2 (es) |
EP (1) | EP2855455B1 (es) |
JP (1) | JP5992096B2 (es) |
KR (1) | KR101666293B1 (es) |
CN (1) | CN104364249B (es) |
AR (1) | AR091185A1 (es) |
AU (1) | AU2013269800A1 (es) |
BR (1) | BR112014026828A2 (es) |
CA (1) | CA2868240A1 (es) |
CL (1) | CL2014002847A1 (es) |
CO (1) | CO7091174A2 (es) |
CR (1) | CR20140481A (es) |
EA (1) | EA201492069A1 (es) |
IL (1) | IL235829A0 (es) |
MX (1) | MX2014014468A (es) |
PE (1) | PE20142366A1 (es) |
PH (1) | PH12014502294A1 (es) |
SG (1) | SG11201406890YA (es) |
TW (1) | TW201402564A (es) |
WO (1) | WO2013178572A1 (es) |
ZA (1) | ZA201407695B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2888324A1 (en) * | 2012-11-07 | 2014-05-15 | Alexander Flohr | Triazolo compounds |
EA201991095A1 (ru) | 2016-11-03 | 2019-09-30 | Бристол-Маерс Сквибб Компани | Замещенные азотсодержащие соединения |
CN111875583B (zh) * | 2017-10-17 | 2021-06-15 | 中国科学院上海药物研究所 | 三氮唑衍生物及其制备方法和用途 |
US20190292188A1 (en) | 2018-02-27 | 2019-09-26 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
PE20211807A1 (es) | 2018-07-05 | 2021-09-14 | Incyte Corp | Derivados de pirazina fusionados como inhibidores de a2a/a2b |
BR112020013697A2 (pt) | 2018-11-06 | 2020-12-01 | H. Lundbeck A/S | compostos para tratamento de sintomas negativos e comprometimentos cognitivos |
WO2020094591A1 (en) | 2018-11-06 | 2020-05-14 | H. Lundbeck A/S | Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
WO2021059220A1 (en) * | 2019-09-25 | 2021-04-01 | Oncoarendi Therapeutics S.A. | Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine |
CN113929634A (zh) * | 2021-11-22 | 2022-01-14 | 山西永津集团有限公司 | 一种2,3-二溴喹喔啉的合成方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2744116A (en) * | 1953-12-04 | 1956-05-01 | Purdue Research Foundation | Bis-(aminotriazolyl-)-hydrocarbons |
AR022229A1 (es) * | 1999-01-12 | 2002-09-04 | Abbott Gmbh & Co Kg | Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion |
US6887870B1 (en) * | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
CA2534432A1 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
JP2008540633A (ja) * | 2005-05-18 | 2008-11-20 | ファイザー・リミテッド | バソプレッシン拮抗薬としての1,2,4−トリアゾール誘導体 |
CA2618963A1 (en) * | 2005-08-10 | 2007-02-15 | Smithkline Beecham Corporation | Xanthine derivatives as selective hm74a agonists |
WO2008103357A1 (en) * | 2007-02-21 | 2008-08-28 | E. I. Du Pont De Nemours And Company | Fungicidal tricyclic 1,2,4-triazoles |
WO2008144767A1 (en) * | 2007-05-21 | 2008-11-27 | Sgx Pharmaceuticals, Inc. | Heterocyclic kinase modulators |
TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物 |
TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
CN103038229B (zh) * | 2010-05-26 | 2016-05-11 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
EP3053924A1 (en) * | 2010-08-12 | 2016-08-10 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d]pyrimidin-4-one derivatives and their use as pde9a inhibitors |
WO2012054366A2 (en) * | 2010-10-21 | 2012-04-26 | Merck Sharp & Dohme Corp. | Substituted amino-triazolyl pde10 inhibitors |
-
2013
- 2013-05-27 WO PCT/EP2013/060838 patent/WO2013178572A1/en active Application Filing
- 2013-05-27 PE PE2014001616A patent/PE20142366A1/es not_active Application Discontinuation
- 2013-05-27 SG SG11201406890YA patent/SG11201406890YA/en unknown
- 2013-05-27 CN CN201380027925.9A patent/CN104364249B/zh not_active Expired - Fee Related
- 2013-05-27 EP EP13725360.5A patent/EP2855455B1/en not_active Not-in-force
- 2013-05-27 MX MX2014014468A patent/MX2014014468A/es unknown
- 2013-05-27 BR BR112014026828A patent/BR112014026828A2/pt not_active Application Discontinuation
- 2013-05-27 AU AU2013269800A patent/AU2013269800A1/en not_active Abandoned
- 2013-05-27 EA EA201492069A patent/EA201492069A1/ru unknown
- 2013-05-27 KR KR1020147036637A patent/KR101666293B1/ko active IP Right Grant
- 2013-05-27 JP JP2015514445A patent/JP5992096B2/ja not_active Expired - Fee Related
- 2013-05-27 CA CA2868240A patent/CA2868240A1/en not_active Abandoned
- 2013-05-28 TW TW102118823A patent/TW201402564A/zh unknown
- 2013-05-29 AR ARP130101863 patent/AR091185A1/es unknown
-
2014
- 2014-09-26 CO CO14213791A patent/CO7091174A2/es unknown
- 2014-10-10 PH PH12014502294A patent/PH12014502294A1/en unknown
- 2014-10-16 CR CR20140481A patent/CR20140481A/es unknown
- 2014-10-22 ZA ZA2014/07695A patent/ZA201407695B/en unknown
- 2014-10-22 CL CL2014002847A patent/CL2014002847A1/es unknown
- 2014-11-20 IL IL235829A patent/IL235829A0/en unknown
- 2014-11-25 US US14/552,837 patent/US9394311B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CL2014002847A1 (es) | 2015-01-30 |
BR112014026828A2 (pt) | 2017-06-27 |
JP2015518018A (ja) | 2015-06-25 |
PE20142366A1 (es) | 2015-01-10 |
JP5992096B2 (ja) | 2016-09-14 |
EP2855455A1 (en) | 2015-04-08 |
CN104364249B (zh) | 2018-04-17 |
EA201492069A1 (ru) | 2015-03-31 |
CO7091174A2 (es) | 2014-10-21 |
TW201402564A (zh) | 2014-01-16 |
CR20140481A (es) | 2014-11-17 |
EP2855455B1 (en) | 2017-11-08 |
MX2014014468A (es) | 2015-02-12 |
KR101666293B1 (ko) | 2016-10-13 |
CA2868240A1 (en) | 2013-12-05 |
KR20150027143A (ko) | 2015-03-11 |
PH12014502294A1 (en) | 2014-12-15 |
CN104364249A (zh) | 2015-02-18 |
SG11201406890YA (en) | 2014-11-27 |
US20150148332A1 (en) | 2015-05-28 |
ZA201407695B (en) | 2016-08-31 |
US9394311B2 (en) | 2016-07-19 |
IL235829A0 (en) | 2015-02-01 |
AU2013269800A1 (en) | 2014-10-09 |
WO2013178572A1 (en) | 2013-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR091185A1 (es) | Derivados de 1,2,4-triazol | |
AR088449A1 (es) | Benzilindazoles sustituidos | |
AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR090488A1 (es) | Derivados de n-ciclobutilbenzamida, un proceso para su obtencion, intermediarios para su sintesis, composiciones pesticidas y farmaceuticas que los comprenden y metodos para controlar daños debidos a una plaga y/u hongos | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
AR089699A1 (es) | Imidazoles y pirazoles fusionados sustituidos y sus usos | |
ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
AR092568A1 (es) | Derivados triciclicos de quinolinas y de quinoxalinas | |
AR087711A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos | |
PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
ES2603931T3 (es) | Compuestos de triazolo | |
ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
AR087771A1 (es) | Moduladores de la pde10 | |
AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
AR097755A1 (es) | Derivados sustituidos de fenilalanina como moduladores del factor xia | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
AR100940A1 (es) | Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |